The 2026 North Central Section of the AUA annual meeting featured a bladder cancer session and a presentation by Dr. Kaitlin Davis discussing regional disparities in bladder cancer mortality rates.

(UroToday.com) The 2026 North Central Section of the AUA annual meeting featured a prostate cancer session and a presentation ...

The 2026 North Central Section of the AUA annual meeting featured a urothelial carcinoma session and a presentation by Dr.

Advanced prostate cancer is one of the leading causes of cancer mortality in men and is often characterized by disease progression through therapeutic evasion followed by metastasis. Emerging evidence ...

In this article, we assess histologically validated quantitative parameters on 18F-piflufolastat (18F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating ...

Andrea Apolo presents a bone metastasis subanalysis from CheckMate-9ER, encompassing roughly 650 patients with metastatic clear cell renal cell carcinoma, around 25% of whom had bone metastases ...

Kenshiro Shiraishi reports 10-year findings from MRI-guided salvage radiotherapy following radical prostatectomy. In a prospective single-arm trial with 40 patients utilizing 3-Tesla multiparametric ...

Andrea Apolo discusses three nectin-4 ADC trials. EV-302's 3.5-year follow-up showed median overall survival of 33.6 months with enfortumab vedotin plus pembrolizumab, and 30% of patients achieved ...

Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Michael Ong describes the TRIPLE-SWITCH trial design, a phase 3 study randomizing patients with metastatic hormone-sensitive prostate cancer and PSA of 0.2 or above at six to twelve months of ADT plus ...

The management of metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved into a complex landscape of doublet and triplet combination strategies. While treatment intensification was ...